Rna Diagnostics is a Canadian company with a patented platform technology providing real-time cancer therapy guidance.
Rna Diagnostics is an early-stage molecular diagnostics company developing medical diagnostic tools to assist in the management of cancer. The company's first product, the RNA Disruption AssayTM (RDATM), is a novel test that helps oncologists rapidly assess the effectiveness of cancer chemotherapy.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 26, 2019 | Series A | — | 1 | — | — | Detail |
Nov 9, 2018 | Series A | $5M | 1 |
|
— | Detail |
Jan 15, 2016 | Angel | — | 3 | — | — | Detail |
Sep 21, 2015 | Angel | $800K | — | — | — | Detail |
Mar 27, 2012 | Angel | $0.92M | 7 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
|
Yes | Series A |
![]() |
— | Series A |
![]() |
— | Angel |
![]() |
— | Angel |
![]() |
— | Angel |
![]() |
— | Angel |
|
— | Angel |
![]() |
— | Angel |
![]() |
— | Angel |
![]() |
— | Angel |